Diabetic kidney disease has a high global disease burden and substantially increases the
risk of kidney failure and cardiovascular events. Despite treatment, there is substantial …

This review covers the last 80 years of remarkable progress in the development of
mineralocorticoid receptor (MR) antagonists (MRAs) from synthesis of the first …

Background Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has
favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 …

Background Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist,
reduced albuminuria in short-term trials involving patients with chronic kidney disease …

Chronic kidney disease (CKD) is the leading complication in type 2 diabetes (T2D) and
current therapies that limit CKD progression and the development of cardiovascular disease …

Chronic kidney disease (CKD) is a chronic renal dysfunction syndrome that is characterized
by nephron loss, inflammation, myofibroblasts activation, and extracellular matrix (ECM) …

Diabetic kidney disease (DKD) is the major cause of end-stage kidney disease. However,
only renin-angiotensin system inhibitor with multidisciplinary treatments is effective for DKD …

Management of diabetic kidney disease (DKD) has evolved in parallel with our growing
understanding of the multiple interrelated pathophysiological mechanisms that involve …

Introduction: The nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone and
sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated clinical benefits in …

Based on global estimates, almost 10% of adults have diabetes, of whom 40% are estimated
to also have chronic kidney disease (CKD). Almost 2 decades ago, treatments targeting the …